HomeCompareINDT vs ABBV

INDT vs ABBV: Dividend Comparison 2026

INDT yields 1.07% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $7.2K in total portfolio value
10 years
INDT
INDT
● Live price
1.07%
Share price
$66.99
Annual div
$0.72
5Y div CAGR
60.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95.1K
Annual income
$36,670.94
Full INDT calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — INDT vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINDTABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INDT + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INDT pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INDT
Annual income on $10K today (after 15% tax)
$91.36/yr
After 10yr DRIP, annual income (after tax)
$31,170.30/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, INDT beats the other by $10,114.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INDT + ABBV for your $10,000?

INDT: 50%ABBV: 50%
100% ABBV50/50100% INDT
Portfolio after 10yr
$98.7K
Annual income
$30,721.35/yr
Blended yield
31.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

INDT
Analyst Ratings
4
Buy
3
Hold
Consensus: Buy
Price Target
$81.00
+20.9% upside vs current
Range: $81.00 — $81.00
Altman Z
2.1
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INDT buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINDTABBV
Forward yield1.07%3.06%
Annual dividend / share$0.72$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR60.7%40.6%
Portfolio after 10y$95.1K$102.3K
Annual income after 10y$36,670.94$24,771.77
Total dividends collected$70.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$81.00$256.15

Year-by-year: INDT vs ABBV ($10,000, DRIP)

YearINDT PortfolioINDT Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,873$172.72$11,550$430.00$677.00ABBV
2$11,916$282.04$13,472$627.96$1.6KABBV
3$13,214$464.22$15,906$926.08$2.7KABBV
4$14,912$773.17$19,071$1,382.55$4.2KABBV
5$17,267$1,310.43$23,302$2,095.81$6.0KABBV
6$20,754$2,278.80$29,150$3,237.93$8.4KABBV
7$26,321$4,113.72$37,536$5,121.41$11.2KABBV
8$35,998$7,835.36$50,079$8,338.38$14.1KABBV
9$54,613$16,094.54$69,753$14,065.80$15.1KABBV
10$95,107$36,670.94$102,337$24,771.77$7.2KABBV

INDT vs ABBV: Complete Analysis 2026

INDTStock

INDUS Realty Trust, Inc. is a real estate business principally engaged in developing, acquiring, managing and leasing industrial/warehouse properties. INDUS owns 41 buildings totaling approximately 4.6 million square feet (4.2 million of which is industrial/warehouse space) in Connecticut, Pennsylvania, North Carolina and Florida in addition to over 3,400 acres of undeveloped land.

Full INDT Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this INDT vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INDT vs SCHDINDT vs JEPIINDT vs OINDT vs KOINDT vs MAININDT vs JNJINDT vs MRKINDT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.